Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMH75KV)

• Drug Name: Acenocoumarol Drug Info
• Synonyms: Acenocoumarin; Acenocoumarolum; Acenocumarol; Acenocumarolo; Acenocumarolum; Acenokumarin; Ascumar; Minisintrom; Neositron;Nicoumalone; Nicumalon; Nitrovarfarian; Nitrowarfarin; Sincoumar; Sinkumar; Sinthrom; Sinthrome; Sintrom; Sintroma; Syncoumar; Syncumar; Synthrom; Syntrom; Zotil; Acenocoumarol Alliance Brand; Acenocoumarol Novartis Brand; Acenocoumarol [INN]; Acenocumarolo [DCIT]; Acenokumarin [Czech]; Alliance Brand of Acenocoumarol; Ciba Geigy Brand of Acenocoumarol; Mini Sintrom; Novartis Brand of Acenocoumarol; G 23350; Acenocoumarol (INN); Acenocoumarol Ciba-Geigy Brand; Acenocoumarolum [INN-Latin]; Ciba-Geigy Brand of Acenocoumarol; G-23350; Mini-sintrom; Sinthrome (TN); Sintrom (TN); AB-014/25000129; G-23,350; Mini-sintrom (TN); Nitrophenylacetylethyl-4-hydroxycoumarine; 2-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-4h-chromen-4-one; 2-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]chromen-4-one; 3-(alpha-(4'-Nitrophenyl)-beta-acetylethyl)-4-hydroxycoumarin; 3-(alpha-(p-Nitrophenol)-beta-acetylethyl)-4-hydroxycoumarin; 3-(alpha-Acetonyl-4-nitrobenzyl)-4-hydroxycoumarin; 3-(alpha-Acetonyl-p-nitrobenzyl)-4-hydroxycoumarin; 3-(alpha-Acetonyl-para-nitrobenzyl)-4-hydroxy-coumarin; 3-(alpha-p-Nitrophenyl-beta-acetylethyl)-4-hydroxycoumarin; 4-Hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)-2H-1-benzopyran-2-one;4-Hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-one
• Therapeutic Class: Anticoagulants
• Cross-matching ID:
  PubChem CID: 54676537
  ChEBI ID: CHEMBL53766
  CAS Number: CAS 152-72-7
  TTD Drug ID: D05HFY
  INTEDE Drug ID: DR0036

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Primary bile acid biosynthesis	1.79	4.34e-2	15/17 (88.24%)	CYP7A1;CYP39A1;CH25H;...
Base excision repair	1.77	3.52e-2	29/33 (87.88%)	POLE2;FEN1;PCNA;...
Gap junction	-1.60	4.61e-2	72/88 (81.82%)	KRAS;ADRB1;HTR2A;...
Ferroptosis	-1.65	3.34e-2	36/41 (87.8%)	HMOX1;ACSL5;ACSL1;...
Fatty acid biosynthesis	-1.65	3.46e-2	16/18 (88.89%)	ACSL3;ACACB;ACSBG1;...
Cholesterol metabolism	-1.67	3.09e-2	44/50 (88%)	TSPO;LRP1;SOAT1;...
Galactose metabolism	-1.70	2.33e-2	26/31 (83.87%)	GALE;GLA;LALBA;...
Toxoplasmosis	-1.72	1.88e-2	103/112 (91.96%)	CYCS;BIRC2;GNAO1;...
Huntington disease	-1.75	1.79e-2	233/306 (76.14%)	ATP5PF;BBC3;TUBB1;...
Leishmaniasis	-1.77	1.70e-2	67/77 (87.01%)	EEF1A1;ITGA4;IL1B;...
Autoimmune thyroid disease	-1.77	1.71e-2	46/53 (86.79%)	HLA-E;HLA-DOA;FAS;...
RNA polymerase	-1.79	1.47e-2	23/31 (74.19%)	POLR2I;POLR1D;POLR3K;...
Antigen processing and presentation	-1.79	1.55e-2	60/78 (76.92%)	HSPA6;HLA-E;HLA-DOA;...
Systemic lupus erythematosus	-1.80	1.63e-2	45/135 (33.33%)	HLA-DPA1;FCGR2A;HLA-DPB1;...
Type II diabetes mellitus	-1.83	1.42e-2	42/46 (91.3%)	SOCS2;CACNA1D;PKM;...
Prion disease	-1.83	1.50e-2	209/273 (76.56%)	GRIN1;COX7B;NDUFC1;...
Regulation of lipolysis in adipocytes	-1.84	1.34e-2	52/55 (94.55%)	ADRB1;ADCY3;ADRB2;...
GABAergic synapse	-1.84	1.43e-2	76/89 (85.39%)	GNG5;GNAO1;GABRA5;...
Non-alcoholic fatty liver disease	-1.84	1.54e-2	126/155 (81.29%)	COX7B;NDUFC1;NDUFB1;...
Neutrophil extracellular trap formation	-1.86	1.34e-2	101/189 (53.44%)	MAPK11;FPR2;GP1BA;...
Platelet activation	-1.86	1.46e-2	106/124 (85.48%)	MAPK1;APBB1IP;RAP1A;...
Retrograde endocannabinoid signaling	-1.86	1.59e-2	118/148 (79.73%)	NDUFC1;NDUFB1;GNG5;...
Graft-versus-host disease	-1.89	1.08e-2	32/42 (76.19%)	HLA-E;HLA-DOA;FAS;...
Phagosome	-1.90	1.05e-2	118/152 (77.63%)	TUBB1;CTSL;MSR1;...
Staphylococcus aureus infection	-1.91	1.18e-2	72/95 (75.79%)	FCGR2B;KRT15;FPR2;...
Diabetic cardiomyopathy	-1.93	7.69e-3	162/203 (79.8%)	COX7B;PDK3;NDUFC1;...
Asthma	-1.94	8.97e-3	25/31 (80.65%)	HLA-DPA1;HLA-DPB1;TNF;...
Ribosome	-1.97	5.38e-3	113/158 (71.52%)	RPL24;MRPS12;MRPL35;...
Parkinson disease	-2.01	3.36e-3	176/249 (70.68%)	HTRA2;COX7B;NDUFC1;...
Oxidative phosphorylation	-2.04	0.00e+0	93/133 (69.92%)	ATP5PF;ATP6V0A2;PPA2;...
Allograft rejection	-2.06	0.00e+0	32/38 (84.21%)	HLA-E;HLA-DOA;FAS;...
Type I diabetes mellitus	-2.32	0.00e+0	38/43 (88.37%)	HLA-E;HLA-DOA;PTPRN;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	6.66uM	6H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 2.22uM	24H	Show ▼

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.04uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.04uM - 10uM	24H	Show ▼